Amgen Hopes Sentiment Swings Sweeter for Myeloma Drug at Key Blood Cancer Meeting

December 6, 2014 4:02 PM

15 0

SAN FRANCISCO (TheStreet) -- Scientists and investors are getting their first detailed look this weekend at a large study of Amgen's (AMGN) multiple myeloma drug Kyprolis. The study, known as ASPIRE, is a key component of Amgen's strategy to boost Kyprolis sales and not incidentally, justify the high cost to acquire the drug.

Kyprolis is approved in the U.S. as a treatment for multiple myeloma patients no longer responding to any other drugs. But sales generated to date ($240 million in the first three quarters of this year) have been a bit disappointing, lagging, for instance, Celgene's (CELG) Pomalyst, which is also ap...

Read more

To category page